By sector
Spot concentrations at a glance. Share of the fund's portfolio, as supplied by FE fundinfo, last updated 8 Oct 2026.
Biotechnology/Medical100.0%
Global X ETFs ISIN AU0000028110
Global X S&P Biotech ETF
Global X S&P Biotech ETF is a passive equity ETF from Global X ETFs, ISIN AU0000028110.
- Passive
- Equity
- United States
The investment objective of the Fund is to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index
How the fund has returned, and where it ranks among peers. Returns to Sep 2026 end, GBP net total return.
+60.5%
1 year return
+96.6%
3 year return
+26.6%
5 year return
Daily NAV, percent change from the start of the range. Source: FE fundinfo.
- 1 month −0.7%
- 3 months −1.1%
- Volatility, 3 years 27.3%
- Ongoing charge (OCF)
What the fund holds
Where the money is: sectors, countries and largest holdings. As supplied by FE fundinfo, last updated 8 Oct 2026. Swipe or use the arrows for more panels.
By country
Spot concentrations at a glance. Share of the fund's portfolio, as supplied by FE fundinfo, last updated 8 Oct 2026.
USA100.0%
By asset class
Spot concentrations at a glance. Share of the fund's portfolio, as supplied by FE fundinfo, last updated 8 Oct 2026.
US Equities100.0%
Largest holdings
The biggest positions, and how concentrated the fund is. As supplied by FE fundinfo, last updated 8 Oct 2026.
-
1. MODERNA, INC.2.1%
-
2. TWIST BIOSCIENCE CORPORATION2.0%
-
3. NATERA INC1.8%
-
4. UNITED THERAPEUTICS CORPORATION1.6%
-
5. ABBVIE INC.1.6%
See all holdingsA free account shows the full list.
Macro events and this fund
Recent events linked to this fund by its country and sector exposure, and how it moved after. A measured move, not a cause.
Performance, risk and facts
Judge return, risk and cost before a client conversation. Relative return uses the chart's time range. Facts as reported by the manager.
Against its benchmark
How the fund compares with its benchmark over the same period.
Risk
How bumpy the ride has been, plus the regulatory risk rating.
Volatility, 3 years27.3%
Scale 0 to 40%
Sharpe ratio, 3 years (FE)0.70
Scale −1 to 3
- Largest fall from a peak (maximum drawdown), 3 years
- −32.8%
Volatility and maximum drawdown: calculated by Funds Benchmark, as at 30 Sep 2026.
Sharpe, alpha, beta: FE fundinfo, as at 7 Jul 2026.
Fund facts
Legal and cost facts for a client note. As reported by the manager.
- ISIN
- AU0000028110
- Fund manager
- ETFS Management (AUS) Limited
- Management company
- ETFS Management (AUS) Limited
- Depositary
- JP Morgan Chase Bank, N.A.
- Benchmark
- S&P Biotechnology Select Industry Index
- Ongoing charge
- Share class launch date
- 8 Nov 2018
- Domicile
- AU
- Fund type
- open-ended fund
What a sum would have become
What an amount would have grown to over the period.
n/a
Past performance is not a reliable guide to future returns. Capital is at risk. Source: FE fundinfo. Returns are GBP net total return to month end unless stated. Headline returns to Sep 2026. Fund size is shown in GBP.
Managed by Global X ETFs
Other FE Gl Not Yet Assigned funds
Sector: FE Gl Not Yet Assigned
View the FE Gl Not Yet Assigned sector overview — top funds, average performance, exposure →
Top country exposure
Add funds to compare
Asset
Style